- Home
- ESPR vs HRZN Comparison
ESPR vs HRZN Comparison
Compare ESPR & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- HRZN
- Stock Information
- Founded
- ESPR 2008
- HRZN 2008
- Country
- ESPR United States
- HRZN United States
- Employees
- ESPR N/A
- HRZN N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- HRZN Finance/Investors Services
- Sector
- ESPR Health Care
- HRZN Finance
- Exchange
- ESPR Nasdaq
- HRZN Nasdaq
- Market Cap
- ESPR 305.0M
- HRZN 341.0M
- IPO Year
- ESPR 2013
- HRZN 2010
- Fundamental
- Price
- ESPR $0.95
- HRZN $8.39
- Analyst Decision
- ESPR Buy
- HRZN Hold
- Analyst Count
- ESPR 7
- HRZN 5
- Target Price
- ESPR $6.07
- HRZN $9.20
- AVG Volume (30 Days)
- ESPR 5.5M
- HRZN 411.3K
- Earning Date
- ESPR 05-06-2025
- HRZN 04-29-2025
- Dividend Yield
- ESPR N/A
- HRZN 16.08%
- EPS Growth
- ESPR N/A
- HRZN N/A
- EPS
- ESPR N/A
- HRZN N/A
- Revenue
- ESPR $332,314,000.00
- HRZN $99,915,000.00
- Revenue This Year
- ESPR $5.17
- HRZN $12.95
- Revenue Next Year
- ESPR N/A
- HRZN $8.81
- P/E Ratio
- ESPR N/A
- HRZN N/A
- Revenue Growth
- ESPR 185.66
- HRZN N/A
- 52 Week Low
- ESPR $0.93
- HRZN $7.55
- 52 Week High
- ESPR $3.94
- HRZN $12.63
- Technical
- Relative Strength Index (RSI)
- ESPR 22.73
- HRZN 42.45
- Support Level
- ESPR $0.93
- HRZN $8.04
- Resistance Level
- ESPR $1.06
- HRZN $8.55
- Average True Range (ATR)
- ESPR 0.09
- HRZN 0.39
- MACD
- ESPR -0.02
- HRZN -0.04
- Stochastic Oscillator
- ESPR 3.57
- HRZN 42.64
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services and sustainability industries.